WESTMINSTER, CO—March 20, 2015—Surefire Medical, Inc., a commercial stage medical device company developing novel devices for minimally invasive, direct-to-tumor interventional procedures, today announced that the company has won Jefferson County Economic Development Corporation’s Innovative Technology Award.

“I extend my deepest congratulations to Surefire for their well-deserved innovation award and their continued contribution to Jefferson County,” Congressman Ed Perlmutter said. Surefire Medical relocated to Jefferson County last year, consolidating manufacturing and R&D facilities into a 21,000 square foot facility that brought 39 high-paying jobs to the county.

The company’s one-of-a-kind Surefire Infusion System, used by interventional radiologists, results in increased penetration of embolic agents into tumors while protecting healthy tissue with a unique telescoping tip that prevents backflow, according to a growing body of clinical research. With older microcatheter technology, only a portion of the dose was delivered to liver tumors, 80 percent of which are inoperable.

Surefire’s technology may also speed procedure time significantly, resulting in a 70 percent reduction in fluoroscopy exposure for greater patient and physician safety according to a recently published study.

About Surefire Medical
Surefire Medical, Inc., based in Westminster, Colo., was founded in 2009 to develop innovative infusion systems for the Interventional Radiology and Interventional Oncology markets. Surefire’s infusion systems are designed to precisely deliver embolic agents through a unique microcatheter with an expandable tip that collapses in forward flow and dynamically expands to the vessel wall in reverse flow in order to maximize targeted delivery, minimize reflux and reduce damage to healthy tissue. The Surefire Infusion System and specialty catheters have received regulatory approval in the U.S., Europe, Canada, Australia, New Zealand and Taiwan. www.surefiremedical.com


Clinical Data Shows Surefire Technology Achieved 79% Objective Response versus 37% Using a Standard Microcatheter in Treating Primary Liver Cancer. Study presented at SIR 2017 Annual Scientific Meeting.